RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.